Initiator Pharma announces last day of trading in warrants of series TO 2
The exercise period for warrants of series TO 2 (“TO 2”), which were issued in connection with Initiator Pharma A/S's (“Initiator Pharma” or “the Company”) rights issue and directed issue of units in June 2020, runs until the 15th of December 2020. The last day of trading in TO 2 is tomorrow, Friday the 11th of December 2020. Holders of TO 2 have the right to, for each warrant, subscribe for one new share in Initiator Pharma at a price of SEK 4.90. Upon full exercise of all warrants, Initiator Pharma will receive approximately
SEK 16.4 million before issue costs – capital that will be used to finance the completion of the clinical phase II study for the drug candidate IP2018.
For the warrants not to expire worthless, it is required that holders of TO 2 subscribe for new shares by exercising warrants no later than Tuesday, the 15th of December 2020, alternatively sell their warrants on the 11th of December 2020, at the latest. TO 2 is traded on Spotlight Stock Market under the ticker INIT TO 2.
Please note that banks/nominees may set different time limits for subscription. Holders of TO 2 are therefore recommended to contact their bank/nominee and set aside time for handling instructions and payment. This is to ensure that the holder acts before the exercise period ends.
Teaser and application form, in both Swedish and English, are available on Initiator Pharma’s (www.initiatorpharma.com) and Sedermera Fondkommission's (www.sedermera.se) respective websites.
Important dates in connection with the exercise period for warrants of series TO 2
• 11 December 2020 - Last day of trading in warrants
• 15 December 2020 – The exercise period ends
• 18 December 2020 - Planned date for publication of outcome
• 4 January 2021 - Planned date for conversion of the warrant exercise outcome
Sedermera Fondkommission is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor in connection with the warrant exercise.
For further information about the warrants of series TO 2, please contact:
Phone: +46 40-615 14 10
E-mail: [email protected]
For further information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Phone: +45 6126 0035
E-mail: [email protected]
About Initiator Pharma
Initiator Pharma is a clinical-stage biotechnology company based in Aarhus, Denmark. The company’s main clinical Phase assets are IPED2015, intended for patients with erectile dysfunction, and IP2018, for the treatment of psychogenic erectile dysfunction. The treatments both represent First in Class treatments for psychogenic and organic ED, respectively, and are expected to improve the quality of life for a growing number of patients who are not responding to or cannot be treated with existing drugs on the market. Read more on www.initiatorpharma.com.
About Erectile dysfunction (ED)
Erectile dysfunction is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. ED affects more than 150 million men worldwide and that number is expected to increase to more than 320 million by 2025, fuelled by aging demographics and increasing prevalence of lifestyle diseases such as diabetes, and performance anxiety. The number of ED patients is most likely grossly underestimated, particularly for Psychogenic patient segment. ED patients have decreased quality of life due to various psychosocial factors such as low self-esteem, depression, sadness, anger, frustration, anxiety, medication, and relationship problems (1,2,3). Erectile dysfunction can be divided into two main categories – Organic and Psychogenic ED – that requires different treatments. Initiator Pharma is developing IPED2015 and IP2018, respectively, for these similar but separate patient segments.
- Shabsigh R, et al. (1998) Increased incidence of depressive symptoms in men with erectile dysfunction. Urology52(5):848–852.
- Mccabe MP, Althof SE (2014) A systematic review of the psychosocial outcomes associated with erectile dysfunction: Does the impact of erectile dysfunction extend beyond a man’s inability to have sex? J Sex Med11(2):347–363.
- Nguyen HMT, Gabrielson AT, Hellstrom WJG (2017) Erectile Dysfunction in Young Men—A Review of the Prevalence and Risk Factors. Sex Med Rev5(4):508–520.
ADDvise acquires Medisuite, LLC
ADDvise Group AB has today entered into a share purchase agreement with the owner of Medisuite LLC regarding the acquisition of all the outstanding shares of Medisuite, LLC in accordance with the letter of intent communicated via a press release dated 24th May 2021. Closing of the acquisition is exp...
ADDvise förvärvar Medisuite, LLC
Medisuite är ett amerikanskt online-apotek, baserat i Cary, North Carolina, som specialiserat sig på läkemedel inom segmentet ”men’s health” för behandling av cancer, inkontinens och impotens. Bolaget har licenser att distribuera läkemedel i samtliga USA:s delstater förutom två. Bedömningen är att B...
Kallelse till årsstämma i Biovica International AB
Information med anledning av coronavirusetBolaget värnar om sina aktieägares och anställdas hälsa och välbefinnande. Det är viktigt för Bolaget att ta ett samhällsansvar och bidra till att begränsa risken för smittspridning av Covid‑19. Mot bakgrund av den extraordinära situation som råder kommer år...
Notice of annual general meeting in Biovica International AB
Information with respect to the coronavirusThe Company is mindful of the health and well-being of its shareholders and employees. It´s important for the Company to take a social responsibility and contribute to reduce the risk of transmission of the Covid-19. Due to the extraordinary situation the a...